Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.12 USD | +0.74% | -11.26% | +61.75% |
Financials (USD)
Sales 2024 * | 71.56M | Sales 2025 * | 277M | Capitalization | 5.62B |
---|---|---|---|---|---|
Net income 2024 * | -437M | Net income 2025 * | -307M | EV / Sales 2024 * | 78.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 20.2 x |
P/E ratio 2024 * |
-9.67
x | P/E ratio 2025 * |
-16.1
x | Employees | 628 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 20.69% |
Latest transcript on ImmunityBio, Inc.
1 day | +0.74% | ||
1 week | -11.26% | ||
Current month | +1.63% | ||
1 month | +58.90% | ||
3 months | +71.31% | ||
6 months | +161.09% | ||
Current year | +61.75% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Adcock
CEO | Chief Executive Officer | 55 | 20-09-30 |
Founder | 71 | 14-11-30 | |
David Sachs
DFI | Director of Finance/CFO | 46 | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 71 | 14-11-30 | |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 19-05-31 |
Wesley Clark
BRD | Director/Board Member | 78 | 21-02-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 8.12 | +0.74% | 4,112,241 |
24-05-09 | 8.06 | +1.77% | 4,499,599 |
24-05-08 | 7.92 | -4.12% | 5,212,663 |
24-05-07 | 8.26 | +5.76% | 9,581,369 |
24-05-06 | 7.81 | -14.64% | 10,789,460 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.75% | 5.62B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- IBRX Stock